| Identification | Back Directory | [Name]
2-Pyridinecarboxamide, N-[2-[trans-4-[[4-[[trans-3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]cyclobutyl]oxy]-1-piperidinyl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- | [CAS]
2573302-50-6 | [Synonyms]
KTX-955
2-Pyridinecarboxamide, N-[2-[trans-4-[[4-[[trans-3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]cyclobutyl]oxy]-1-piperidinyl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- | [Molecular Formula]
C46H51F3N8O7 | [MOL File]
2573302-50-6.mol | [Molecular Weight]
884.94 |
| Hazard Information | Back Directory | [Uses]
KTX-955 is an antumor and effective IRAK4 degrader, with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively[1]. KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735). | [IC 50]
IRAK4: 5 nM (IC50) | [References]
[1] Matthew Weiss. Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications. Northeastern Section, ACS (NESACS).
[2] Nello Mainolfi, et al. Irak degraders and uses thereof. WO2020264499A1 |
|
|